• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Large Basal Cell Carcinoma

Article

The lesion’s location, along with visible telangiectasia on the lesion’s surface, suggest a basal cell carcinoma.

A gradually enlarging nodule on the pre-auricular facial skin developed in a 68-year-old man who was otherwise in good health. The lesion was asymptomatic. There was no regional adenopathy.

Key point: The lesion’s location, along with visible telangiectasia on the lesion’s surface, suggest a basal cell carcinoma. Biopsy verified this tentative diagnosis.

Treatment: Because of the lesion’s size (2 cm x 2 cm) and location (near branches of the facial nerve), Moh’s surgery with microscopic control was performed, rather than deep excision.  

Note: While basal cell carcinoma only rarely metastasizes, it can cause important anatomical disruption in select areas and may require very careful removal.

Related Content
Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Grace Halsey
February 7th 2025
Article

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Grace Halsey
February 7th 2025
Article

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Grace Halsey
February 5th 2025
Article

Improvement in

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose / image credit: ©New Africa/AdobeStock

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Sydney Jennings
February 5th 2025
Article

Your daily dose of the clinical news you may have missed.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial / image credit Sonja Molin, MD Queen’s University

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Grace Halsey
February 4th 2025
Article

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis / image credit courtesy of OHSU

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis

Grace Halsey
January 27th 2025
Article

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

© 2025 MJH Life Sciences

All rights reserved.